The Center for Translational Injury Research (CeTIR) at UTHealth Houston is conducting upcoming clinical trials aimed at advancing trauma care. These studies focus on improving resuscitation techniques and enhancing blood clotting strategies to reduce complications and improve patient outcomes. Through innovative research, CeTIR continues to explore new approaches to trauma treatment that can save lives and improve recovery for critically injured patients.
| Allogenic adipose derived mesenchymal stromal cells (MSC) for acute kidney injury after trauma or burn |
|---|
| PI – Charles Cox, MD |
| Co-Investigators – Erin Fox, PhD; John Harvin, MD; Laura Moore, MD; Claudia Pedroza, PhD |
| Supporting Agency - Department of Defense via Medical Technology Enterprise Consortium (MTEC) and Wake Forest Institute for Regenerative Medicine |
| Background: Acute kidney injury (AKI), an abrupt decline in renal function that occurs over hours to days, occurs in up to 50% of trauma and burn patients. There are few effective therapies for trauma- and burn-associated AKI aside from supportive care and dialysis. Cellular therapies, specifically mesenchymal stem cell (MSC) therapies, offer promise in addressing multiple therapeutic targets in trauma and burns that current resuscitation approaches and supportive care cannot achieve. MSCs can potentially 1) safeguard cells and prevent further damage; 2) alter the microenvironment by addressing inflammatory mediators; and 3) trigger self-regenerative and reparative processes related to end-organ injury. Hypothesis/Objectives: This proposal seeks to explore the safety and therapeutic potential of multi-dose, adipose tissue-derived MSCs in the treatment of KDIGO Stage 2 AKI in trauma and burn patients. We hypothesize that infusing 3 doses of MSCs daily for 3 days in patients with Stage 2 AKI will prove to be safe and efficacious. Our objectives are: |
|